BIODEXA PHARMA is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3(TM) platform for delivering therapeutics across the blood-brain barrier and the treatment of central nervous system disorders in areas of high unmet medical need. BIODEXA PHARMA, formerly known as Midatech Pharma plc, is based in NEW HAVEN, Conn....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 21 December 2024
2023-05-14 12:31:00 Sunday ET
Paul Samuelson defines the mathematical evolution of economic price theory and thereby influences many economists in business cycle theory and macro asset m
2018-05-09 08:31:00 Wednesday ET
CBS and its special committee of independent directors have decided to sue the Redstone controlling shareholders because these directors might have breached
2022-03-25 09:34:00 Friday ET
Corporate cash management The empirical corporate finance literature suggests four primary motives for firms to hold cash. These motives include the tra
2019-11-06 12:29:00 Wednesday ET
Our fintech finbuzz analytic report shines fresh light on the fundamental prospects of U.S. tech titans Facebook, Apple, Microsoft, Google, and Amazon (F.A.
2020-05-21 11:30:00 Thursday ET
Most blue-ocean strategists shift fundamental focus from current competitors to alternative non-customers with new market space. W. Chan Kim and Renee Ma
2022-10-25 11:31:00 Tuesday ET
Corporate investment insights from mergers and acquisitions Relative market misvaluation between the bidder and target firms drives most waves of mergers